Providing leverage for a small-molecule program targeted at heart failure, Cytokinetics Inc. is collaborating with Amgen Inc. in a deal potentially worth $725 million. (BioWorld Today)

Nearly three years after moving its first agent into Phase I trials, Spirogen Ltd. is starting off 2007 with similar plans for a second compound. (BioWorld Today)

As a stem cell company preparing to enter clinical trials in 2007, Neuralstem Inc. began trading last week on the Over-the-Counter Bulletin Board. (BioWorld Today)

Biotech tools company CombiMatrix Corp. has filed to list its stock on the American Stock Exchange in a move to separate itself from parent Acacia Research Corp. (BioWorld Today)

As Kosan Biosciences Inc. focuses on its cancer therapeutics, it licensed out its motilin agonist program to Pfizer Inc. in a worldwide deal worth up to $250 million in up-front and milestone payments. (BioWorld Today)